Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

@article{Brantley2007AssociationOC,
  title={Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.},
  author={Milam A. Brantley and Amy M. Fang and Jennifer M. King and Asheesh Tewari and Steven M. Kymes and Alan Shiels},
  journal={Ophthalmology},
  year={2007},
  volume={114 12},
  pages={
          2168-73
        }
}
PURPOSE To investigate whether there is an association between complement factor H (CFH) or LOC387715 genotypes with response to treatment with intravitreal bevacizumab for exudative age-related macular degeneration (AMD). DESIGN Retrospective cohort study. PARTICIPANTS The study cohort consisted of 86 patients being treated for neovascular AMD with bevacizumab alone. METHODS Genotype determination for the CFH Y402H and LOC387715 A69S polymorphisms was performed by allele-specific… Expand
Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab
TLDR
In this study cohort, the response to treatment of AMD with ranibizumab differed according to CFH genotype, suggesting that determining patients’ CFHgenotype may be helpful in the future in tailoring treatment for exudative AMD with intravitreal ranibIZumab. Expand
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy
TLDR
The CFH Y402H variant was associated with a response to PDT treatment in this study, and patients with the CFH TT genotype fared significantly worse with PDT than did those with theCFH TC and CC genotypes, suggesting a potential relationship between CFH genotype andresponse to PDT. Expand
Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population
TLDR
HTRA1 gene polymorphism may influence patient response to treatment with intravitreal ranibizumab for neovascular AMD, and there was no significant difference in central retinal thickness and maximum lesion thickness among the genotypes of the tested single-nucleotide polymorphisms. Expand
Y402H Polymorphism in Complement Factor H and Age-Related Macular Degeneration in the Tunisian Population
TLDR
A strong association of the 402H allele with susceptibility to AMD in the Tunisian population was confirmed; however, this variant does not appear to be involved in the clinical progression of this disease or in the postintravitreal bevacizumab response. Expand
Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration
TLDR
The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population. Expand
CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration
TLDR
Preliminary evidence is reported suggesting that the higher AMD risk genotypes in CFH, VEGF and HTRA1 may influence the short-term response to treatment with ranibizumab for neovascular AMD. Expand
Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population
TLDR
The VEGF-A (rs833069) polymorphism showed a significant association with the anatomic response to intravitreal ranibizumab, and no significant difference was found between the genotype of the potential risk polymorphism for development of AMD and the early visual improvement after intravItal ranibzumab. Expand
Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population
TLDR
This study demonstrated that different LOC387715/HTRA1 genotypes resulted in different bevacizumab treatment responses on exudative AMD, illustrating how pharmacogenetic factors may help determine treatment modality and dosing. Expand
Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
TLDR
The results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population. Expand
GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
TLDR
In this Korean neovascular AMD cohort, there was no statistically significant effect of genotype on early visual outcome after ranibizumab treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
TLDR
The data suggest that the CFH Y402H polymorphism is a major risk factor for exudative AMD in a Central European population of Caucasoid descent. Expand
Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers.
TLDR
The CFH Y402H variant is strongly associated with both GA and CNV in the U.K. population, and heavier smokers with the CC genotype may be at particular risk. Expand
An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment
TLDR
In this UK cohort of AMD patients, the CFH Y402H variant was significantly enriched in patients with predominantly classic CNV, which may influence the biological response of choroidal neovascularisation (CNV) following photodynamic therapy (PDT) for CNV. Expand
No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese
TLDR
The frequency of the C allele of rs1061170 (Y402H) is much lower in Japanese controls than in Caucasians, and CFH does not appear to be a primary hereditary contributor to ARMD in Japanese. Expand
Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
TLDR
A single intravitreal bevacizumab injection was well tolerated and, except for minor transient local adverse events, no other adverse events were observed. Expand
Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population.
TLDR
The results suggest the contribution of the Y402H polymorphism of the CFH gene to exudative AMD susceptibility also in the French population, which may lead to early detection and new strategies for prevention and treatment of AMD. Expand
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration.
TLDR
Common polymorphisms in the genes CFH and LOC387715 are independently related to AMD progression after adjustment for other known AMD risk factors, and presence of these polymorphisms plus smoking and body mass index of 25 or higher, controlling for AREDS vitamin-mineral treatment, identifies patients who are highly susceptible to developing advanced states of this visually disabling disease. Expand
Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration.
TLDR
The Y402H CFH variant carried a significantly increased risk for developing AMD in the authors' population, and genotype and phenotype correlations regarding choroidal neovascular lesion type were observed. Expand
Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.
TLDR
The allele frequency of Y402H polymorphism in CFH has an ethnic variation, with much lower 1277C frequency in Chinese than in white patients, despite this, the polymorphism is significantly associated with neovascular AMD in the Chinese population. Expand
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
TLDR
Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and associated with improvement in VA, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, the majority of whom had previous treatment with photodynamic therapy and/or pegaptanib. Expand
...
1
2
3
4
5
...